Collecting and studying bio-specimens from melanoma patients
Official title: Storage and Research Use of Human Bio-specimens From Melanoma Patients and Clinical Testing for Assignment of Treatment
Run by Vanderbilt-Ingram Cancer Center · NCT01205815 · Data updated 2026-11-12
This study is collecting tissue and blood samples from melanoma patients to learn more about the disease and improve future treatments.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 3000 (estimated) |
| Sponsor | Vanderbilt-Ingram Cancer Center Academic / other |
| Locations | 1 site (Nashville, Tennessee) |
| Status | Recruiting |
| Started | June 3, 2010 |
| Main results expected | June 2027 |
| Study ends | June 2027 |
| Registry record updated | September 19, 2025 |
| Trial ID | NCT01205815 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are individuals with a pathologically-proven diagnosis of melanoma who can provide leftover tissue or blood samples.
✕Probably not a fit
Patients with significant contraindications to blood collection or those unable to provide consent may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This research focuses on collecting tissue and blood samples from patients diagnosed with melanoma to identify biological characteristics associated with the initiation and progression of the disease. The study aims to bank these specimens for future research purposes, which may help in understanding melanoma better and improving treatment strategies. Patients who have undergone diagnostic or therapeutic procedures that yield leftover tissue are eligible to participate. The study is observational and does not involve any specific treatment interventions.
Why it matters
Potential benefit: If successful, this research could lead to improved understanding and treatment options for melanoma patients.
How similar studies have gone: Other studies involving the collection and analysis of bio-specimens from cancer patients have shown success in advancing understanding and treatment options, making this approach promising.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion criteria * Pathologically-proven diagnosis of melanoma. * Patient must have a test or procedure that has the potential to provide left-over tissue that can be banked for future research purposes OR the patient has already had a diagnostic or therapeutic procedure but who has not yet been approached to participate is also eligible. Exclusion criteria * Any patient with significant contraindications to venipuncture (e.g., severe anemia) will be excluded from blood collection procedures. However, if the patient provides consent and a paraffin-embedded block or 10-15 unstained slides of their tissue diagnosis, they will not be excluded from this protocol. * Any patient unable or unwilling to provide consent.
Where it's running
-
Vanderbitl-Ingram Cancer Center
Nashville, Tennessee, United States Recruiting
Study contacts
- Principal investigator: Douglas Johnson, M.D. — Vanderbilt-Ingram Cancer Center
- Study coordinator: Vanderbilt-Ingram Service for Timely Access
- Phone: 800-811-8480
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Melanoma treatment with immunotherapy guided by serial ctDNA testing
This trial tests whether regular ctDNA blood tests during treatment can help tailor the plan for patients with advanced melanoma receiving nivolumab and ipilimumab.
-
Non-invasive skin-tape test to detect melanoma using methylation biomarkers
A non-invasive skin-tape test is being tried to see if it can detect melanoma in people who are about to have a biopsy for a suspicious pigmented lesion.
-
SI-B036 safety test in advanced and metastatic solid tumors
This early-phase study checks whether SI-B036 is safe and tolerable in adults with advanced or metastatic solid cancers who have had prior therapy.
-
BL-M08D treatment in melanoma and other solid tumors
A phase Ib/II study tests BL-M08D1 injections in adults with locally advanced or metastatic melanoma and other solid tumors to see if it is safe and helpful.
-
Aggressive lipid lowering in melanoma patients starting immune checkpoint therapy
This trial tests whether lowering cholesterol aggressively can reduce heart artery disease risk in melanoma patients who are just beginning immune checkpoint therapy.
-
Timing of Immunotherapy in Melanoma
This trial tests whether starting standard melanoma immunotherapy earlier in the day (before 10 am) versus later in the day (after 1 pm) makes a difference for patients with unresectable or metastatic melanoma.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.